ArticleScientific reports2026
Experimental hut evaluation of mosquito shield, a transfluthrin spatial emanator, for control of wild pyrethroid resistant malaria vectors in Benin.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spatial emanators disrupt mosquito behaviour by inducing movement away from chemical stimuli and interfering with host detection and feeding. These tools were recently endorsed by the World Health Organization (WHO) for malaria control, based largely on clinical evidence from East Africa. Mosquito Shield™ is a passive, transfluthrin-based emanator designed to provide month-long protection in enclosed or semi-enclosed spaces. This study evaluated its entomological efficacy under experimental hut conditions in Benin, West Africa to generate evidence in support of WHO prequalification. An experimental hut trial was conducted against wild free-flying pyrethroid-resistant Anopheles gambiae s.l. at the Covè field station in southern Benin over two 32-day product life cycles of Mosquito Shield™. Sixteen West African–style experimental huts were assigned to Mosquito Shield™ or a placebo control. Efficacy was measured using human landing catches (HLC) and mosquito aspirations following standard hut testing methods. Primary endpoints included reductions in the numbers of mosquitoes caught through HLC (protective efficacy) and in the numbers of blood-fed mosquitoes caught through aspiration (personal protection). Secondary endpoints included deterrence, exophily, mortality, and blood-feeding inhibition. WHO susceptibility bioassays confirmed high levels of resistance to pyrethroids, including transfluthrin, in the local Anopheles gambiae s.l. population during the trial. A total of 5,682 An. gambiae s.l. and 6,158 Mansonia africana were collected through HLCs, and 1,436 An. gambiae s.l. by mosquito aspirations. Mosquito Shield™ significantly reduced mosquito landing, providing 43.0% protective efficacy (95% CI: 24.0–57.0; p < 0.001) against An. gambiae s.l. and 38.0% protective efficacy (95% CI: 12.0–57.0; p = 0.008) against Mansonia africana. Mosquito aspiration data showed 48.5% deterrence, 29.9% blood-feeding inhibition, comparable exiting rates between treatment and control huts (47.2% vs. 46.7%; p = 0.962) and 64% personal protection (95% CI: 21.9–81.8; p < 0.001) against An. gambiae s.l. No mosquito mortality was recorded in the control huts. In contrast, Mosquito Shield™ induced mortality of Anopheles gambiae s.l. reaching 49.0% in HLC collections and 22.7% in aspiration collections. Mosquito Shield™ also induced > 96% mortality in Mansonia africana, demonstrating both lethal and behavioural effects against both vector species. Overall, Mosquito Shield™ significantly reduced mosquito entry, landing, blood-feeding, and survival of pyrethroid-resistant An. gambiae s.l. under semi-field experimental hut conditions in West Africa, with additional effects against Mansonia africana. These results support its WHO prequalification and highlight its potential as a complementary vector control tool to strengthen malaria prevention and provide additional benefits for integrated control of other vector-borne diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.